39 related articles for article (PubMed ID: 24139415)
1. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
[TBL] [Abstract][Full Text] [Related]
2. Molecular design and biological activities of NF-kappaB inhibitors.
Umezawa K; Chaicharoenpong C
Mol Cells; 2002 Oct; 14(2):163-7. PubMed ID: 12442886
[TBL] [Abstract][Full Text] [Related]
3. Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Tsai HJ; Kobayashi S; Izawa K; Ishida T; Watanabe T; Umezawa K; Lin SF; Tojo A
Cancer Sci; 2011 Nov; 102(11):2014-21. PubMed ID: 21777350
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth by NF-kappaB inhibitors.
Umezawa K
Cancer Sci; 2006 Oct; 97(10):990-5. PubMed ID: 16925581
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome.
Tanaka T; Kudo K; Kanezaki R; Yuzawa K; Toki T; Okuse R; Kobayashi A; Sato T; Kamio T; Terui K; Ito E
Exp Hematol; 2024 Apr; 132():104179. PubMed ID: 38342295
[TBL] [Abstract][Full Text] [Related]
6. Effect of NF-κβ inhibitor - dehydroxymethylepoxyquinomicin on iron isomaltoside toxicity toward peritoneal mesothelial cells.
Bręborowicz A; Umezawa K
Ren Fail; 2024 Dec; 46(1):2304647. PubMed ID: 38240039
[No Abstract] [Full Text] [Related]
7. Statement of Retraction:
Toxicol Mech Methods; 2024 Feb; 34(2):236. PubMed ID: 38149664
[No Abstract] [Full Text] [Related]
8. Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model.
Kawaguchi M; Yamamoto K; Kanemaru A; Tanaka H; Umezawa K; Fukushima T; Kataoka H
Oncotarget; 2016 Oct; 7(42):68614-68622. PubMed ID: 27612426
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
[TBL] [Abstract][Full Text] [Related]
10. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells.
Togano T; Nakashima M; Watanabe M; Umezawa K; Watanabe T; Higashihara M; Horie R
Oncol Res; 2012; 20(12):571-7. PubMed ID: 24139415
[TBL] [Abstract][Full Text] [Related]
12. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells.
Watanabe M; Umezawa K; Higashihara M; Horie R
Oncol Res; 2013; 21(4):173-80. PubMed ID: 24762223
[TBL] [Abstract][Full Text] [Related]
14. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
15. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
